Background: Voclosporin, a novel calcineurin inhibitor approved for the treatment of lupus nephritis, has proven efficacious in clinical trials; however, its real-world renal safety profile remains incompletely characterized. This study aimed to evaluate renal adverse event signals associated with voclosporin using the FDA Adverse Event Reporting System (FAERS) and to investigate the impact of drug exposure duration and reporter type on signal detection. Methods：Data from the first quarter of 2021 to the fourth quarter of 2025 were extracted from the FAERS database. After data cleaning and deduplication, reports listing voclosporin as the primary suspected drug were assigned to the exposed group, while reports involving other drugs (regardless of role code) served as the comparator group. Renal adverse events were defined using 32 MedDRA preferred terms, and a composite endpoint of proteinuria consisting of 9 terms was constructed. Four algorithms were employed for signal detection: reporting odds ratio (ROR), proportional reporting ratio (PRR), empirical Bayes geometric mean (EBGM05), and information component with Bayesian credible interval (IC025). Stratified analyses were performed by treatment duration (acute ≤30 days, subacute 31–90 days, chronic >90 days, unknown), as well as by gender and reporter type (consumer vs. health professional). Sensitivity analyses included excluding the unknown duration group and stratifying by reporter type. Results：A total of 10,128 voclosporin primary suspect reports and 41,887 other drug reports were included. The study population was predominantly female (85.1%), with 98.9% of reports originating from the United States, and the rate of missing age data was only 3.6%. Overall signal detection revealed positive signals for decreased glomerular filtration rate (EBGM05=1.09, IC025=0.126) and increased urine protein/creatinine ratio (UPCR; EBGM05=1.03, IC025=0.041). For proteinuria (a=186), the overall ROR was 0.45 (95% CI 0.38–0.53), indicating a lower reporting rate in the voclosporin group; it was not among the top 10 signals. However, a borderline positive signal was observed in the unknown duration group (ROR 1.19, 95% CI 1.00–1.42). Time‑stratified analysis showed that all positive signals were confined to reports with unknown treatment duration: UPCR ROR=1.42 (1.14–1.77), and protein urine present ROR=1.59 (1.01–2.52); no signals were observed in known duration groups. Gender stratification revealed that UPCR was positive in females (ROR=1.33, 1.07–1.66), while no signal was detected in males. Reporter type stratification demonstrated a strong positive signal for the composite endpoint in health professional reports (ROR=1.84, 1.56–2.19), whereas consumer reports showed no signal (0.90, 0.76–1.07). Sensitivity analyses excluding the unknown duration group eliminated all signals. Conclusions：Voclosporin is associated with weak but statistically significant renal adverse events. The signals are entirely dependent on reports with missing drug exposure duration and are significantly influenced by reporter type. Missing data on treatment duration severely limits the assessment of time‑risk trends. Clinical monitoring of urine protein/creatinine ratio and glomerular filtration rate is recommended. These findings highlight an urgent need for improved documentation of treatment duration in pharmacovigilance databases.